{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:20Z","timestamp":1790345000662,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This multicenter imaging study aimed to establish and validate automated radiomics models predicting therapy response (TR) and minimal residual response (MRD) in newly diagnosed multiple myeloma (MM) from baseline MRI. Retrospectively, 118 MM patients from the GMMG-HD7 trial (EudraCT: 2017-004768-37) with data on TR and\/or MRD after induction therapy and baseline MRI were included. Data were split by center into a training set (center 1\u20132; <jats:italic>n<\/jats:italic>\u2009=\u200979) and a test set (center 3\u201310; <jats:italic>n<\/jats:italic>\u2009=\u200939). TR was classified as very good partial response or better versus other. An in-house developed nnU-Net was used to automatically segment pelvic bone marrow for the subsequent extraction of 245 radiomics features and piriformis muscle for normalization. Random forest classifiers were trained using radiomics features only (I), radiomics features with additional confounders (II) or myeloma-relevant clinical features (III), or only clinical features (IV) to predict TR or MRD status. The area under the receiver operating characteristic curve (AUROC) was calculated to assess prediction performance. The prediction model using only radiomics features (I) showed the highest predictive performance for TR on the test set with an AUROC of 0.70. AUROC values for radiomics-based prediction of the MRD status (I-III) ranged from 0.54 to 0.52. In conclusion, our study demonstrated the potential of automated radiomics models from baseline MRI to non-invasively predict TR in MM on an independent, multicentric test set.<\/jats:p>","DOI":"10.1038\/s41598-025-13165-2","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:09:17Z","timestamp":1760087357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Fabian","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hajiyianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"K\u00e4chele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Steffen","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim F.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Debic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Horger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Afat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hoffend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Maier-Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wennmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Neher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"13165_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers. 3, 17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"13165_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5 (2014).","journal-title":"Lancet Oncol."},{"key":"13165_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014 (2021).","journal-title":"Ann. Oncol."},{"key":"13165_CR4","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6 (2016).","journal-title":"Lancet Oncol."},{"key":"13165_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"HJ van de Velde","year":"2007","unstructured":"van de Velde, H. J. et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92, 1399\u20131406. https:\/\/doi.org\/10.3324\/haematol.11534 (2007).","journal-title":"Haematologica"},{"key":"13165_CR6","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/jco.2009.25.4250","volume":"28","author":"AA Chanan-Khan","year":"2010","unstructured":"Chanan-Khan, A. A. & Giralt, S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J. Clin. Oncol. 28, 2612\u20132624. https:\/\/doi.org\/10.1200\/jco.2009.25.4250 (2010).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A Meta-analysis. JAMA Oncol. 3, 28\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3160 (2017).","journal-title":"JAMA Oncol."},{"key":"13165_CR8","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/jco.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron, A. C. et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research Council myeloma IX study. J. Clin. Oncol. 31, 2540\u20132547. https:\/\/doi.org\/10.1200\/jco.2012.46.2119 (2013).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder, M. et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the united States. Leukemia 36, 801\u2013808. https:\/\/doi.org\/10.1038\/s41375-021-01453-5 (2022).","journal-title":"Leukemia"},{"key":"13165_CR10","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy, P. L. et al. Lenalidomide maintenance after autologous Stem-Cell transplantation in newly diagnosed multiple myeloma: A Meta-Analysis. J. Clin. Oncol. 35, 3279\u20133289. https:\/\/doi.org\/10.1200\/JCO.2017.72.6679 (2017).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos, M. A. et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J. Clin. Oncol. 33, 657\u2013664. https:\/\/doi.org\/10.1200\/JCO.2014.57.9961 (2015).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mri.2020.10.005","volume":"75","author":"A Latifoltojar","year":"2021","unstructured":"Latifoltojar, A., Boyd, K., Riddell, A., Kaiser, M. & Messiou, C. Characterising Spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: towards macro-phenotype driven patient management. Magn. Reson. Imaging. 75, 60\u201364. https:\/\/doi.org\/10.1016\/j.mri.2020.10.005 (2021).","journal-title":"Magn. Reson. Imaging"},{"key":"13165_CR13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00256-023-04383-8","volume":"52","author":"F Bauer","year":"2023","unstructured":"Bauer, F., Sauer, S., Weinhold, N., Delorme, S. & Wennmann, M. Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at Iliac crest and tumor load shown by MRI. Skeletal Radiol. 52, 2513\u20132518. https:\/\/doi.org\/10.1007\/s00256-023-04383-8 (2023).","journal-title":"Skeletal Radiol."},{"key":"13165_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ajh.23258","volume":"87","author":"LA Moulopoulos","year":"2012","unstructured":"Moulopoulos, L. A. et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am. J. Hematol. 87, 861\u2013864. https:\/\/doi.org\/10.1002\/ajh.23258 (2012).","journal-title":"Am. J. Hematol."},{"key":"13165_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdi362","volume":"16","author":"LA Moulopoulos","year":"2005","unstructured":"Moulopoulos, L. A. et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann. Oncol. 16, 1824\u20131828. https:\/\/doi.org\/10.1093\/annonc\/mdi362 (2005).","journal-title":"Ann. Oncol."},{"key":"13165_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3324\/haematol.2015.124115","volume":"100","author":"EK Mai","year":"2015","unstructured":"Mai, E. K. et al. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica 100, 818\u2013825. https:\/\/doi.org\/10.3324\/haematol.2015.124115 (2015).","journal-title":"Haematologica"},{"key":"13165_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker, R. et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J. Clin. Oncol. 25, 1121\u20131128. https:\/\/doi.org\/10.1200\/JCO.2006.08.5803 (2007).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","volume":"97","author":"J Hillengass","year":"2012","unstructured":"Hillengass, J. et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 97, 1757\u20131760. https:\/\/doi.org\/10.3324\/haematol.2012.065359 (2012).","journal-title":"Haematologica"},{"key":"13165_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-Computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J. Clin. Oncol. 35, 2911\u20132918. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975 (2017).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR20","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass, J. et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 20, e302\u2013e312. https:\/\/doi.org\/10.1016\/S1470-2045(19)30309-2 (2019).","journal-title":"Lancet Oncol."},{"key":"13165_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00256-021-03841-5","volume":"51","author":"FE Lecouvet","year":"2022","unstructured":"Lecouvet, F. E. et al. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the Art WB-MRI and PET\/CT. Skeletal Radiol. 51, 59\u201380. https:\/\/doi.org\/10.1007\/s00256-021-03841-5 (2022).","journal-title":"Skeletal Radiol."},{"key":"13165_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin, P. et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer. 48, 441\u2013446. https:\/\/doi.org\/10.1016\/j.ejca.2011.11.036 (2012).","journal-title":"Eur. J. Cancer"},{"key":"13165_CR23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jamaoncol.2016.2631","volume":"2","author":"HJ Aerts","year":"2016","unstructured":"Aerts, H. J. The potential of Radiomic-Based phenotyping in precision medicine: A review. JAMA Oncol. 2, 1636\u20131642. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2631 (2016).","journal-title":"JAMA Oncol."},{"key":"13165_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41571-022-00707-0","volume":"20","author":"EP Huang","year":"2023","unstructured":"Huang, E. P. et al. Criteria for the translation of radiomics into clinically useful tests. Nat. Rev. Clin. Oncol. 20, 69\u201382. https:\/\/doi.org\/10.1038\/s41571-022-00707-0 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"13165_CR25","doi-asserted-by":"publisher","unstructured":"Li, Y. et al. Radiomics models based on magnetic resonance imaging for prediction of the response to bortezomib-based therapy in patients with multiple myeloma. Biomed. Res. Int. 691:1246 (2022). https:\/\/doi.org\/10.1155\/2022\/6911246","DOI":"10.1155\/2022\/6911246"},{"key":"13165_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/RCT.0000000000001298","volume":"46","author":"Z Wu","year":"2022","unstructured":"Wu, Z. et al. Spinal MRI-Based radiomics analysis to predict treatment response in multiple myeloma. J. Comput. Assist. Tomogr. 46, 447\u2013454. https:\/\/doi.org\/10.1097\/RCT.0000000000001298 (2022).","journal-title":"J. Comput. Assist. Tomogr"},{"key":"13165_CR27","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1016\/j.crad.2023.07.011","volume":"78","author":"X Xiong","year":"2023","unstructured":"Xiong, X. et al. Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods. Clin. Radiol. 78, e839\u2013e846. https:\/\/doi.org\/10.1016\/j.crad.2023.07.011 (2023).","journal-title":"Clin. Radiol."},{"key":"13165_CR28","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt, H. et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 9, e810\u2013e821. https:\/\/doi.org\/10.1016\/S2352-3026(22)00263-0 (2022).","journal-title":"Lancet Haematol."},{"key":"13165_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/RLI.0000000000000891","volume":"57","author":"M Wennmann","year":"2022","unstructured":"Wennmann, M. et al. Combining deep learning and radiomics for automated, objective, comprehensive bone marrow characterization from Whole-Body MRI: A multicentric feasibility study. Invest. Radiol. 57, 752\u2013763. https:\/\/doi.org\/10.1097\/RLI.0000000000000891 (2022).","journal-title":"Invest. Radiol."},{"key":"13165_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/RLI.0000000000000932","volume":"58","author":"M Wennmann","year":"2023","unstructured":"Wennmann, M. et al. Deep learning for automatic bone marrow apparent diffusion coefficient measurements from Whole-Body magnetic resonance imaging in patients with multiple myeloma: A retrospective multicenter study. Invest. Radiol. 58, 273\u2013282. https:\/\/doi.org\/10.1097\/RLI.0000000000000932 (2023).","journal-title":"Invest. Radiol."},{"key":"13165_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/RLI.0000000000000986","volume":"58","author":"M Wennmann","year":"2023","unstructured":"Wennmann, M. et al. Prediction of bone marrow biopsy results from MRI in multiple myeloma patients using deep learning and radiomics. Invest. Radiol. 58, 754\u2013765. https:\/\/doi.org\/10.1097\/RLI.0000000000000986 (2023).","journal-title":"Invest. Radiol."},{"key":"13165_CR32","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J. Clin. Oncol. 33, 2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267 (2015).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR33","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino, M. et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project. J. Clin. Oncol. 40, 3406\u20133418. https:\/\/doi.org\/10.1200\/JCO.21.02614 (2022).","journal-title":"J. Clin. Oncol."},{"key":"13165_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2214\/ajr.161.6.8249729","volume":"161","author":"TB Poulton","year":"1993","unstructured":"Poulton, T. B., Murphy, W. D., Duerk, J. L., Chapek, C. C. & Feiglin, D. H. Bone marrow reconversion in adults who are smokers: MR imaging findings. AJR Am. J. Roentgenol. 161, 1217\u20131221. https:\/\/doi.org\/10.2214\/ajr.161.6.8249729 (1993).","journal-title":"AJR Am. J. Roentgenol."},{"key":"13165_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2214\/AJR.14.13964","volume":"205","author":"I Lavdas","year":"2015","unstructured":"Lavdas, I. et al. Apparent diffusion coefficient of normal abdominal organs and bone marrow from Whole-Body DWI at 1.5 T: the effect of sex and age. AJR Am. J. Roentgenol. 205, 242\u2013250. https:\/\/doi.org\/10.2214\/AJR.14.13964 (2015).","journal-title":"AJR Am. J. Roentgenol."},{"key":"13165_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/RLI.0000000000000838","volume":"57","author":"M Wennmann","year":"2022","unstructured":"Wennmann, M. et al. Repeatability and reproducibility of ADC measurements and MRI signal intensity measurements of bone marrow in monoclonal plasma cell disorders: A prospective Bi-institutional multiscanner, multiprotocol study. Invest. Radiol. 57, 272\u2013281. https:\/\/doi.org\/10.1097\/RLI.0000000000000838 (2022).","journal-title":"Invest. Radiol."},{"key":"13165_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/RLI.0000000000000927","volume":"58","author":"M Wennmann","year":"2023","unstructured":"Wennmann, M. et al. In vivo repeatability and multiscanner reproducibility of MRI radiomics features in patients with monoclonal plasma cell disorders: A prospective Bi-institutional study. Invest. Radiol. 58, 253\u2013264. https:\/\/doi.org\/10.1097\/RLI.0000000000000927 (2023).","journal-title":"Invest. Radiol."},{"key":"13165_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.radonc.2018.11.021","volume":"131","author":"M Gotz","year":"2019","unstructured":"Gotz, M., Nolden, M., Maier-Hein, K. M. I. T. K. & Phenotyping An open-source toolchain for image-based personalized medicine with radiomics. Radiother Oncol. 131, 108\u2013111. https:\/\/doi.org\/10.1016\/j.radonc.2018.11.021 (2019).","journal-title":"Radiother Oncol."},{"key":"13165_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin, P. et al. Radiomics: the Bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 14, 749\u2013762. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"13165_CR40","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"13165_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29442","author":"M Wennmann","year":"2024","unstructured":"Wennmann, M. et al. Reproducible radiomics features from Multi-MRI\u2010Scanner Test\u2013Retest\u2010Study: influence on performance and generalizability of models. J. Magn. Reson. Imaging. https:\/\/doi.org\/10.1002\/jmri.29442 (2024).","journal-title":"J. Magn. Reson. Imaging"},{"key":"13165_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13244-023-01572-w","volume":"15","author":"B Kocak","year":"2024","unstructured":"Kocak, B. et al. METhodological radiomics score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII. Insights Imaging. 15, 8. https:\/\/doi.org\/10.1186\/s13244-023-01572-w (2024).","journal-title":"Insights Imaging"},{"key":"13165_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13244-023-01415-8","volume":"14","author":"B Kocak","year":"2023","unstructured":"Kocak, B. et al. CheckList for evaluation of radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII. Insights Imaging. 14, 75. https:\/\/doi.org\/10.1186\/s13244-023-01415-8 (2023).","journal-title":"Insights Imaging"},{"key":"13165_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837\u2013845 (1988).","journal-title":"Biometrics"},{"key":"13165_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. & Matplotlib A 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395. https:\/\/doi.org\/10.1109\/MCSE.2007.55 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"13165_CR46","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"ML Waskom","year":"2021","unstructured":"Waskom, M. L. & Seaborn Statistical data visualization. J. Open. Source Softw. 6, 3021. https:\/\/doi.org\/10.21105\/joss.03021 (2021).","journal-title":"J. Open. Source Softw."},{"key":"13165_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00330-019-06360-z","volume":"30","author":"JE Park","year":"2020","unstructured":"Park, J. E. et al. Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPOD statement. Eur. Radiol. 30, 523\u2013536. https:\/\/doi.org\/10.1007\/s00330-019-06360-z (2020).","journal-title":"Eur. Radiol."},{"key":"13165_CR48","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","volume":"34","author":"H Goldschmidt","year":"2020","unstructured":"Goldschmidt, H. et al. Response-adapted Lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 34, 1853\u20131865. https:\/\/doi.org\/10.1038\/s41375-020-0724-1 (2020).","journal-title":"Leukemia"},{"key":"13165_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.12.060","author":"F Bauer","year":"2025","unstructured":"Bauer, F. et al. Advanced automated model for robust bone marrow segmentation in whole-body MRI. Acad. Radiol. https:\/\/doi.org\/10.1016\/j.acra.2024.12.060 (2025).","journal-title":"Acad. Radiol."},{"key":"13165_CR50","doi-asserted-by":"publisher","first-page":"e241613","DOI":"10.1148\/radiol.241613","volume":"314","author":"T Akinci D\u2019Antonoli","year":"2025","unstructured":"Akinci D\u2019Antonoli, T. et al. TotalSegmentator MRI: Robust Sequence-independent Segmentation of Multiple Anatomic Structures in MRI. Radiology 314, e241613. https:\/\/doi.org\/10.1148\/radiol.241613 (2025).","journal-title":"Radiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13165-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:02:58Z","timestamp":1760130178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13165-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13165"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13165-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest regarding the submitted work. Outside of the submitted work, the following relationships are reported: MH: honoraria: Sanofi.MSR: consulting or advisory role: BMS, Amgen, GSK, Janssen, Sanofi, Pfizer, AbbVie, Novartis, and Roche; research funding: Sanofi; travel accommodation and expenses: BMS, AbbVie, Janssen, Sanofi, and GSK; Honoraria: BMS, Janssen, GSK, AbbVie, and Sanofi; receipt of equipment, materials, drugs, medical writing, gifts or other services: Novartis and Sanofi.SS: travel grants or honoraria: Celgene, BMS, Janssen, Takeda, and Amgen. BB: honoraria: Janssen, GSK, AMGEN, Pfizer, Oncopeptides, and Sanofi.UG: stock and other ownership interests: Biontech; honoraria: Boehringer Ingelheim, Amgen, AstraZeneca, Bristol-Myers Squibb, MSD Oncology, Sanofi Aventis GmbH, Fujifilm, Cellrion, Ipsen, and Novartis; consulting or advisory role: Amgen and MSD Oncology; research funding: Ipsen and Macrogenics; travel, accomodations or expenses: Boehringer Ingelheim and GSK.JD: advisory board and travel support: Amgen, BMS, Janssen, Sanofi, and Takeda; honoraria: Amgen, BMS, Janssen, and Sanofi.LU: advisory board: EasyRadiology; speaker: Siemens Healthineers and Bayer Healthcare. HPS: consulting fee or honoraria: Siemens, Curagita, Profound, and Bayer; travel support: Siemens, Curagita, Profound, and Bayer; board member: Curagita; consultancy: Curagita and Bayer; payment for lectures: Siemens, Curagita, Profound, and Bayer.HG: grants and\/or provision of investigational medicinal products: Amgen, Array Biopharma\/Pfizer, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, and Sanofi; research support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme, MorphoSys AG, Pfizer, Sanofi, Takeda, and Novartis; advisory board: Adaptive Biotechnology, Amgen, BMS, Janssen, and Sanofi; honoraria: Amgen, BMS, Chugai, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Pfizer. EKM: consulting or advisory role: Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; honoraria: Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; research funding: Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda; travel accommodations and expenses: Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35400"}}